Sumitomo Dainippon Pharma Competitors

Abacus Health Products (OTCMKTS:ABAHF) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Abacus Health Products and Sumitomo Dainippon Pharma, as provided by MarketBeat.com.

Profitability

This table compares Abacus Health Products and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Abacus Health Products and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Acreage (OTCMKTS:ACRGF) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Acreage and Sumitomo Dainippon Pharma, as provided by MarketBeat.com.

Acreage currently has a consensus price target of $8.4333, indicating a potential upside of 204.45%. Given Acreage's higher possible upside, research analysts plainly believe Acreage is more favorable than Sumitomo Dainippon Pharma.

Profitability

This table compares Acreage and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Acreage and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Summary

Acreage beats Sumitomo Dainippon Pharma on 2 of the 2 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Applied Biosciences and Sumitomo Dainippon Pharma, as provided by MarketBeat.com.

Profitability

This table compares Applied Biosciences and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Applied Biosciences and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Ayr Strategies (OTCMKTS:AYRSF) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Ayr Strategies and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ayr Strategies and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ayr Strategies and Sumitomo Dainippon Pharma, as provided by MarketBeat.com.

Ayr Strategies currently has a consensus price target of $34.8571, indicating a potential upside of 63.96%. Given Ayr Strategies' higher possible upside, research analysts plainly believe Ayr Strategies is more favorable than Sumitomo Dainippon Pharma.

Summary

Ayr Strategies beats Sumitomo Dainippon Pharma on 2 of the 2 factors compared between the two stocks.

Can B (NASDAQ:CANB) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Can B and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Can B and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Can B and Sumitomo Dainippon Pharma, as reported by MarketBeat.

Cansortium (OTCMKTS:CNTMF) and Sumitomo Dainippon Pharma (OTCMKTS:DNPUF) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Cansortium and Sumitomo Dainippon Pharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Cansortium and Sumitomo Dainippon Pharma's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Cansortium and Sumitomo Dainippon Pharma, as reported by MarketBeat.

Cansortium currently has a consensus price target of $1.20, indicating a potential upside of 18.81%. Given Cansortium's higher possible upside, equities analysts clearly believe Cansortium is more favorable than Sumitomo Dainippon Pharma.

Summary

Cansortium beats Sumitomo Dainippon Pharma on 2 of the 2 factors compared between the two stocks.